CBR1 is a cytoplasmic enzyme that plays a significant role in the detoxification of reactive carbonyl compounds. It has a broad substrate specificity and is known to reduce a variety of carbonyl-containing compounds to their corresponding alcohols . The enzyme’s activity is essential for the metabolism of several therapeutic drugs and the detoxification of harmful substances.
The PAT2D6AT clone is a monoclonal antibody developed in mice that specifically targets human CBR1 . Monoclonal antibodies are produced by identical immune cells that are clones of a unique parent cell, ensuring specificity and uniformity in their action. The PAT2D6AT clone is particularly useful in various scientific applications, including:
These applications are crucial for detecting and quantifying CBR1 in different biological samples, aiding in research related to cell biology, metabolism, and signal transduction.
CBR1 antibodies, including the PAT2D6AT clone, are valuable tools in biomedical research. They help in studying the expression and function of CBR1 in various tissues and under different physiological and pathological conditions. Understanding CBR1’s role can provide insights into its involvement in drug metabolism, resistance mechanisms, and its potential as a therapeutic target.